- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07848165
Probiotic Role in Prevention of Ventilator Associated Pneumonia in Critically- Ill Children Admitted at Pediatric Intensive Care Unit
Assessment of Probiotic Role in Prevention of Ventilator Associated Pneumonia in Critically- Ill Children Admitted at Pediatric Intensive Care Unit
The aim of the work is to evaluate the impact of Probiotics supplementation on prevention of ventilator associated pneumonia in critically ill children admitted at Pediatric Intensive Care Unit at Tanta University Hospitals.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Critically ill children are the children whom requiring, or potentially requiring, high reliance or serious consideration whether in medical, surgical or trauma-related fields.
Based on the time of onset of Ventilator Associated Pneumonia (VAP), it can be divided into two types. Early-onset VAP occurs during the first four days of mechanical ventilation and is usually caused by antibiotic sensitive bacteria. Late-onset VAP develops five or more days after initiation of MV and is caused by multidrug-resistant (MDR) pathogens .VAP is associated with a high rate of all-cause mortality and a prolonged duration of mechanical ventilation and intensive care unit stay.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Yomna G El-Feky, MD
- Telefonnummer: 00201005562005
- E-mail: Youmna.elfeky@med.tanta.edu.eg
Studiesteder
-
-
Al Gharbia
-
Tanta, Al Gharbia, Egypten, 31739
- Rekruttering
- Tanta University
-
Kontakt:
- Yomna G El-Feky, MD
- Telefonnummer: 00201005562005
- E-mail: Youmna.elfeky@med.tanta.edu.eg
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Critically ill children from 1 month to 18 years.
- Both sexes.
- Ventilated not due to chest infection.
Exclusion Criteria:
- Children recently received enteral vaccines.
- Children receiving chronic immunosuppressive such as chemotherapy agents. and immunosuppressive medications, and high dose corticosteroids (more than 1 milligram per kilogram).
- Children with contraindications of enteral feeding.
- Children with gastrointestinal bleeding.
- Children with open wounds following major surgery.
- Children with short gut syndrome.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Group I
Critically ill ventilated children will receive standard management plus probiotics. |
Critically ill ventilated children will receive standard management plus probiotics. |
|
Aktiv komparator: Group II
Critically ill ventilated children will receive standard management only. |
Critically ill ventilated children will receive standard management only. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of ventilator-associated pneumonia
Tidsramme: During the first 28 days after initiation of mechanical ventilation
|
Incidence of ventilator-associated pneumonia (VAP) diagnosed according to predefined CDC/NHSN pediatric criteria |
During the first 28 days after initiation of mechanical ventilation
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of mechanical ventilation
Tidsramme: Up to 28 days
|
Duration of invasive mechanical ventilation will be measured in days from initiation of mechanical ventilation until successful extubation. |
Up to 28 days
|
|
Pediatric intensive care unit length of stay
Tidsramme: Up to 28 days
|
Pediatric intensive care unit (PICU) length of stay will be measured in days from PICU admission until PICU discharge. |
Up to 28 days
|
|
Incidence of mortality
Tidsramme: Up to 28 days
|
Incidence of mortality will be recorded. |
Up to 28 days
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sundhedsrelateret lungebetændelse
- Patologiske processer
- Sygdomsegenskaber
- Luftvejsinfektioner
- Infektioner
- Luftvejssygdomme
- Lungesygdomme
- Lungebetændelse
- Krydsinfektion
- Iatrogen sygdom
- Patologiske tilstande, tegn og symptomer
- Lungebetændelse, Ventilator-Associated
- Kosttilskud
- Mad
- Diæt, mad og ernæring
- Fysiologiske fænomener
- Mad og drikkevarer
- Probiotika
Andre undersøgelses-id-numre
- 36264MS985/6/25
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
IPD-delingstidsramme
After the end of study for one year.
IPD-delingsadgangskriterier
The data will be available upon a reasonable request from the corresponding author.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .